Robert Paul1, Wasana Prasitsuebsai2, Neda Jahanshad3, Thanyawee Puthanakit2,4, Paul Thompson3, Linda Aurpibul5, Rawiwan Hansudewechakul6, Pope Kosalaraksa7, Suparat Kanjanavanit8, Chaiwat Ngampiyaskul9, Wicharn Luesomboon10, Sukalaya Lerdlum11, Mantana Pothisri11, Pannee Visrutaratna12, Victor Valcour13, Talia M Nir3, Arvin Saremi3, Stephen Kerr2,14,15, Jintanat Ananworanich2,14,16. 1. From the Missouri Institute of Mental Health, University of Missouri, St. Louis, Missouri. 2. HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand. 3. Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, California. 4. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 5. Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. 6. Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 7. Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 8. Nakornping Hospital, Chiang Mai, Thailand. 9. Prapokklao Hospital, Chantaburi, Thailand. 10. Queen Savang Vadhana Memorial Hospital, Chongburi, Thailand. 11. Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 12. Department of Radiology, Chiang Mai University, Chiang Mai, Thailand. 13. Memory and Aging Center, Department of Neurology, University of California, San Francisco, California. 14. The University of Amsterdam, Amsterdam, the Netherlands. 15. The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. 16. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland.
Abstract
BACKGROUND: Children with vertically acquired HIV exhibit persistent cognitive impairments, yet the corresponding neuroimaging signature of vertical infection remains unclear. METHODS: Fifty healthy control children and 51 vertically infected children were included in the study. The HIV-infected group consisted of survivors who had not received antiretroviral therapy at birth. The HIV-infected group averaged 11.4 (2.5) years of age, with a median CD4 count of 683 cells/mm(3). Most (71%) of the HIV-infected children were on antiretroviral therapy for a median of 34 months (range: 33-42) with HIV RNA <40 copies/mL in 89% of the sample. The HIV-uninfected group averaged 10.6 (2.6) years of age. Magnetic resonance imaging was acquired to determine volumes of the caudate, putamen, thalamus, pallidum, hippocampus, nucleus accumbens, total white matter, total gray matter and cortical gray matter. Correlational analyses examined the degree of shared variance between brain volumes and both cognitive performances and laboratory markers of disease activity (T cells and plasma viral load). RESULTS: HIV-infected children exhibited larger volumes of the caudate, nucleus accumbens, total gray matter and cortical gray matter when compared with the controls. Volumetric differences were predominately evident in children under 12 years of age. HIV-infected children performed worse than controls on most neuropsychologic tests, though neither cognitive performances nor laboratory markers corresponded to brain volumes in the HIV-infected children. CONCLUSIONS: Outcomes of the present study suggest abnormal brain maturation among HIV-infected pediatric survivors. Longitudinal studies of brain integrity and related resilience factors are needed to determine the impact of neuroimaging abnormalities on psychosocial function in pediatric HIV.
BACKGROUND:Children with vertically acquired HIV exhibit persistent cognitive impairments, yet the corresponding neuroimaging signature of vertical infection remains unclear. METHODS: Fifty healthy control children and 51 vertically infectedchildren were included in the study. The HIV-infected group consisted of survivors who had not received antiretroviral therapy at birth. The HIV-infected group averaged 11.4 (2.5) years of age, with a median CD4 count of 683 cells/mm(3). Most (71%) of the HIV-infectedchildren were on antiretroviral therapy for a median of 34 months (range: 33-42) with HIV RNA <40 copies/mL in 89% of the sample. The HIV-uninfected group averaged 10.6 (2.6) years of age. Magnetic resonance imaging was acquired to determine volumes of the caudate, putamen, thalamus, pallidum, hippocampus, nucleus accumbens, total white matter, total gray matter and cortical gray matter. Correlational analyses examined the degree of shared variance between brain volumes and both cognitive performances and laboratory markers of disease activity (T cells and plasma viral load). RESULTS:HIV-infectedchildren exhibited larger volumes of the caudate, nucleus accumbens, total gray matter and cortical gray matter when compared with the controls. Volumetric differences were predominately evident in children under 12 years of age. HIV-infectedchildren performed worse than controls on most neuropsychologic tests, though neither cognitive performances nor laboratory markers corresponded to brain volumes in the HIV-infectedchildren. CONCLUSIONS: Outcomes of the present study suggest abnormal brain maturation among HIV-infected pediatric survivors. Longitudinal studies of brain integrity and related resilience factors are needed to determine the impact of neuroimaging abnormalities on psychosocial function in pediatric HIV.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Jana E Jones; Daren C Jackson; Karlee L Chambers; Kevin Dabbs; David A Hsu; Carl E Stafstrom; Michael Seidenberg; Bruce P Hermann Journal: Epilepsia Date: 2015-01-12 Impact factor: 5.864
Authors: Mario Ortega; Jodi M Heaps; John Joska; Florin Vaida; Soraya Seedat; Dan J Stein; Robert Paul; Beau M Ances Journal: J Neurovirol Date: 2013-10 Impact factor: 2.643
Authors: James T Becker; Joanne Sanders; Sarah K Madsen; Ann Ragin; Lawrence Kingsley; Victoria Maruca; Bruce Cohen; Karl Goodkin; Eileen Martin; Eric N Miller; Ned Sacktor; Jeffery R Alger; Peter B Barker; Priyanka Saharan; Owen T Carmichael; Paul M Thompson Journal: Brain Imaging Behav Date: 2011-06 Impact factor: 3.978
Authors: Anne S De Groot; Bill Jesdale; William Martin; Caitlin Saint Aubin; Hakima Sbai; Andrew Bosma; Judy Lieberman; Gail Skowron; Fadi Mansourati; Kenneth H Mayer Journal: Vaccine Date: 2003-10-01 Impact factor: 3.641
Authors: Sophie Cohen; Matthan W A Caan; Henk-Jan Mutsaerts; Henriette J Scherpbier; Taco W Kuijpers; Peter Reiss; Charles B L M Majoie; Dasja Pajkrt Journal: Neurology Date: 2015-11-11 Impact factor: 9.910
Authors: Neda Jahanshad; Peter V Kochunov; Emma Sprooten; René C Mandl; Thomas E Nichols; Laura Almasy; John Blangero; Rachel M Brouwer; Joanne E Curran; Greig I de Zubicaray; Ravi Duggirala; Peter T Fox; L Elliot Hong; Bennett A Landman; Nicholas G Martin; Katie L McMahon; Sarah E Medland; Braxton D Mitchell; Rene L Olvera; Charles P Peterson; John M Starr; Jessika E Sussmann; Arthur W Toga; Joanna M Wardlaw; Margaret J Wright; Hilleke E Hulshoff Pol; Mark E Bastin; Andrew M McIntosh; Ian J Deary; Paul M Thompson; David C Glahn Journal: Neuroimage Date: 2013-04-28 Impact factor: 6.556
Authors: Malon Van den Hof; Anne Marleen Ter Haar; Matthan W A Caan; Rene Spijker; Johanna H van der Lee; Dasja Pajkrt Journal: Neurol Clin Pract Date: 2019-10
Authors: Benjamin S C Wade; Victor G Valcour; Thanyawee Puthanakit; Arvin Saremi; Boris A Gutman; Talia M Nir; Christa Watson; Linda Aurpibul; Pope Kosalaraksa; Pradthana Ounchanum; Stephen Kerr; Netsiri Dumrongpisutikul; Pannee Visrutaratna; Jiraporn Srinakarin; Monthana Pothisri; Katherine L Narr; Paul M Thompson; Jintanat Ananworanich; Robert H Paul; Neda Jahanshad Journal: Neuroimage Clin Date: 2019-04-02 Impact factor: 4.881
Authors: Lee Fairlie; Miriam Chernoff; Mark F Cotton; Mutsa Bwakura-Dangarembizi; Avy Violari; Itziar Familiar-Lopez; Linda Barlow-Mosha; Portia Kamthunzi; Katie McCarthy; Patrick Jean-Philippe; Barbara Laughton; Paul E Palumbo; Michael J Boivin Journal: Front Pediatr Date: 2022-08-03 Impact factor: 3.569
Authors: Isaac L Khobo; Marcin Jankiewicz; Martha J Holmes; Francesca Little; Mark F Cotton; Barbara Laughton; Andre J W van der Kouwe; Allison Moreau; Emmanuel Nwosu; Ernesta M Meintjes; Frances C Robertson Journal: Hum Brain Mapp Date: 2022-05-16 Impact factor: 5.399